Rajeev Ayyagari
Education
Ph.D., biostatistics, Harvard University; M.S., computer science, University of Maryland; M.A. and B.A., statistics, Indian Statistical Institute
Summary of Experience
Dr. Ayyagari is experienced in applying statistical techniques to the study of clinical and economic outcomes in a broad range of disease areas, including diabetes, cardiovascular disease, oncology, psychiatry, immunology, and infectious diseases. His expertise includes comparative efficacy and safety, risk prediction, missing data problems, identification of causal effects in observational studies, robust estimation, indirect and mixed treatment comparisons, and applications of artificial intelligence (AI) and large language models to health care. Dr. Ayyagari’s recent work includes evaluating the comparative efficacy of inhibitors in diabetes for regulatory submissions, assessing the causal effect of adherence on diabetes outcomes, developing stroke risk models incorporating pulse pressure, developing a social experiment on attitudes towards people with movement disorders, leading the development of software tools to communicate the economic value of therapies, and leading the deployment of generative AI-based systems for automated literature summarization. His research has been published in the Journal of the American Statistical Association, Journal of the National Cancer Institute, Cancer Treatment Reviews, Pediatric Pulmonology, and elsewhere. Dr. Ayyagari has also presented his work at health care and data mining conferences. Prior to joining Analysis Group, he was a research fellow at the Harvard School of Public Health and a biostatistician with Information Management Services, Inc.
-
Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US
BMC Cancer, 2024
2024Whitman ED, Totev TI, Jiang S, da Costa WL Jr, Grebennik D, Wang H, Boca AE, Ayyagari R
-
Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States
Clinical and Translational Gastroenterology, 2024
2024Lembo A, Cash BD, Lu M, Terasawa E, Terreri B, Du S, Ayyagari R, Feuerstadt P, Moshiree B, Westermeyer B, Pi S, Boules M
-
Impact of Tardive Dyskinesia on Physical, Psychological, Social, and Professional Domains of Patient Lives: A Survey of Patients in the United States
Journal of Clinical Psychiatry, 2023
2023Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S
-
Safety Differences across Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Future Oncology, 2023
2023Shore N, Garcia-Horton V, Terasawa E, Ayyagari R, Grossman JP, Waldeck AR
-
Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations
Clinical Kidney Journal, 2023
2023Sackeyfio A, Lopes RD, Kovesdy CP, Cases A, Mallett SA, Ballew N, Keeley TJ, Garcia-Horton V, Ayyagari R, Camejo RR, Johansen KL, Sutton AJ, Dasgupta I
-
Impact of tardive dyskinesia on patients and caregivers: a survey of caregivers in the United States
Journal of Patient-reported Outcomes, 2023
2023Jain R, Ayyagari R, Goldschmidt D, Zhou M, Finkbeiner S, Leo S
-
Health-care resource use and costs associated with diabetic and idiopathic gastroparesis: A claims analysis of the first 3 years following the diagnosis of gastroparesis
Neurogastroenterology & Motility, 2022
2022Chen YJ, Tang W, Ionescu-Ittu R, Ayyagari R, Wu E, Huh SY, Parkman HP
-
The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison
Advances in Therapy, 2022
2022Shore N, Jiang S, Garcia-Horton V, Terasawa E, Steffen D, Chin A, Ayyagari R, Partridge J, Waldeck AR
-
Long-term burden of respiratory complications associated with extreme prematurity: An analysis of US Medicaid claims
Pediatrics & Neonatology, 2022
2022Mowitz ME, Gao W, Sipsma H, Zuckerman P, Wong H, Ayyagari R, Sarda SP, Siffel C
-
Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
-
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers
Cancers (Basel), 2022
2022Garcia-Foncillas J, Bokemeyer C, Italiano A, Keating K, Paracha N, Fellous M, Marian M, Fillbrunn M, Gao W, Ayyagari R, Lassen U
-
Defining Utility Values for Chorea Health States in Patients with Huntington's Disease
Advances in Therapy, 2022
2022Claassen DO, Ayyagari R, Goldschmidt D, Zhou M, Leo S, Ribalov R
-
Defining utility values for patients with tardive dyskinesia
Current Medical Research and Opinion, 2022
2022Ayyagari R, Goldschmidt D, Zhou M, Ribalov R, Caroff SN, Leo S
-
Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington's Disease: A Retrospective Database Analysis
Neurology and Therapy, 2022
2022Claassen DO, Ayyagari R, Garcia-Horton V, Zhang S, Alexander J, Leo S
-
Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study
The Journal of Headache and Pain, 2022
2022Driessen MT, Cohen JM, Patterson-Lomba O, Thompson SF, Seminerio M, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R
-
Burden of Comorbidities and Healthcare Resource Utilization among Medicaid-Enrolled Extremely Premature Infants
Journal of Health Economics and Outcomes Research, 2022
2022Mowitz ME, Gao W, Sipsma H, Zuckerman P, Wong H, Ayyagari R, Sarda SP
-
Disruption of Pharmacotherapy During the Transition from Adolescence to Early Adulthood in Patients with Attention-Deficit/Hyperactivity Disorder: A Claims Database Analysis Across the USA
CNS Drugs, 2021
2021Farahbakhshian S, Ayyagari R, Barczak DS, Gill SK, Tang W, Kulalert T, Jenkins M, Spalding W
-
Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
The Journal of Urology, 2021
2021Halabi S, Jiang S, Terasawa E, García-Horton V, Ayyagari R, Waldeck AR, Shore N
-
The Risk Reduction of Accidental Exposure-Related Systemic Allergic Reactions Extrapolated Based on Food Challenge Data After 1 Year of Peanut Oral Immunotherapy
Advances in Therapy, 2021
2021Yu S, Smith A, Hass S, Wu E, Chai X, Zhou J, Ayyagari R, Liu JS, Robison D, Donelson SM, Tilles S
-
The Impact of Antipsychotic Dose Reduction on Clinical Outcomes and Health Care Resource Use Among Medicare Patients with Schizophrenia
Clinical Drug Investigation, 2021
2021Zichlin ML, Mu F, Leo S, Ayyagari R
-
Indirect Comparison of Darolutamide Versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
Journal of Urology, 2021
2021Halabi S, Jiang S, Terasawa E, Garcia-Horton V, Ayyagari R, Waldeck AR, Shore N
-
Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
Diabetes Therapy, 2020
2020Peng XV, Ayyagari R, Lubwama R, Shi L, Price-Haywood EG, Hollander P, Fonseca V
-
Hospital utilization rates following antipsychotic dose reduction in mood disorders: implications for treatment of tardive dyskinesia
BMC Psychiatry, 2020
2020Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B
-
Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders
Journal of Medical Economics, 2020
2020Ayyagari R, Thomason D, Mu F, Philbin M, Carroll B
-
Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia
Expert Review of Pharmacoeconomics & Outcomes Research, 2020
2020Mowitz ME, Mangili A, Han L, Ayyagari R, Gao W, Wang J, Zhao J, Sarda SP
-
Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis
Journal of Comparative Effectiveness Research, 2020
2020Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J
-
Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome
Therapeutic Advances in Gastroenterology, January 1, 2019
2019Lacy B, Ayyagari R, Guérin A, Lopez A, Shi S, Luo M
-
Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer
Breast Journal, 2019
2019Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA
-
Health Care Burden of Bronchopulmonary Dysplasia Among Extremely Preterm Infants
Frontiers in Pediatrics, 2019
2019Mowitz ME, Ayyagari R, Gao W, Zhao J, Mangili A, Sarda SP
-
The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders
Current Medical Research and Opinion, 2019
2019McEvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B
-
Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
Journal of Blood Medicine, 2019
2019Batt K, Gao W, Ayyagari R, Deschaseaux C, Vashi PB, Yao Z, Wang Y, Kessabi S, Klamroth R
-
Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index
Acta Dermato-Venereologica, 2019
2019Ariëns LFM, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, Chen Z, Bégo-Le Bagousse G, Lu Y, Rizova E, Graham NMH, Pirozzi G, De Bruin-Weller M, Eckert L
-
Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer: A Network Meta-analysis
Clinical Therapeutics. Apr 2018;40(4):628-639 e623
2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA
-
A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment
The Journal of Clinical Hypertension. 2018 Jun;20(6):1058-1066
2018Ayyagari R, Xie J, Cheng D, Wu EQ, Huang XY, Chen S
-
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis
Current Medical Research and Opinion. 2018 Sep;34(9):1645-1652
2018Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA
-
Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.
Advances in Therapy. Dec 2017;34(12):2566-2584
2017Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA
-
A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK
Eur J Health Econ. Jan 2018;19(1):21-35
2017Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA
-
Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors
American Health and Drug Benefits. November 2017;10(8):408-415
2017Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB
-
Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
European Child and Adolescent Psychiatry. Aug 2017;26(8):875-897
2017Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V
-
Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment
Diabetes Therapy, 2016 09; 7(3): 439-454. e-pub ahead of print 2016/08/10; doi: 10.1007/s13300-016-0189-4
2016Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH
-
Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
Journal of Blood Medicine, 2016 07; 7: 129-137. e-pub ahead of print 2016/07/23
2016Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J
-
Brentuximab Vedotin Compared with Other Therapies in Relapsed/Refractory Hodgkin Lymphoma Post ASCT: Median Overall Survival Meta-Analysis
Curr Med Res Opin. 2015 May 7:1-48
2015Bonthapally V, Yang H, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D
-
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care
Pediatr Pulmonol. 2013 Oct;48(10):954-61
2012Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L
-
November 17, 2024
-
May 5, 2024